ErbB2/Her2 anticorps (AA 1242-1255)

N° du produit ABIN967459

Cet anticorps Souris Monoclonal détecte spécifiquement ErbB2/Her2 dans WB, IP, IHC (p) et IHC (fro). Il présente une réactivité envers Humain et a été mentionné dans 7+ publications.

Aperçu rapide pour ErbB2/Her2 anticorps (AA 1242-1255) (ABIN967459)

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ErbB2/Her2 est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: 3B5

Détail du produit anti-ErbB2/Her2 anticorps

Épitope: AA 1242-1255

Marque: BD Pharmingen™

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Human c-erbB-2 aa. 1242-1255

Isotype: IgG1

Information d'application

Indications d'application: Applications include immunoprecipitation (1-2 µg/one million cells), western blot analysis (1-2 µg/ml), and immunohistochemistry of frozen and formalin-fixed paraffin-embedded tissue sections (5-20 µg/ml). Positive control cell lines include MCF7 cells (ATCC HTB 22) and SK-BR-3 (ATCC HTB 30) human breast carcinoma cells.

Commentaires:

Related Products: ABIN968585, ABIN967389

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4°C.

Références pour anticorps anti-ErbB2/Her2 (ABIN967459)

Carraway, Cantley: "A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling." dans: Cell, Vol. 78, Issue 1, pp. 5-8, (1994) (PubMed).

Martinazzi, Crivelli, Zampatti, Martinazzi: "Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study." dans: Pathologica, Vol. 85, Issue 1100, pp. 637-44, (1994) (PubMed).

Penault-Llorca, Adelaïde, Houvenaeghel, Hassoun, Birnbaum, Jacquemier: "Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation." dans: The Journal of pathology, Vol. 173, Issue 1, pp. 65-75, (1994) (PubMed).

Schwechheimer, Läufle, Schmahl, Knödlseder, Fischer, Höfler: "Expression of neu/c-erbB-2 in human brain tumors." dans: Human pathology, Vol. 25, Issue 8, pp. 772-80, (1994) (PubMed).

Singleton, Niehans, Gu, Litz, Hagen, Qiu, Kiang, Strickler: "Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry." dans: Human pathology, Vol. 23, Issue 10, pp. 1141-50, (1992) (PubMed).

Zhau, Zhang, von Eschenbach, Scorsone, Babaian, Ro, Hung: "Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer." dans: Molecular carcinogenesis, Vol. 3, Issue 5, pp. 254-7, (1991) (PubMed).

van de Vijver, Peterse, Mooi, Wisman, Lomans, Dalesio, Nusse: "Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer." dans: The New England journal of medicine, Vol. 319, Issue 19, pp. 1239-45, (1988) (PubMed).

Détails sur ErbB2/Her2

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Autre désignation: c-erbB-2

Sujet: C-erbB-2 (also known as HER2/neu), a 185 kDa transmembrane glycoprotein, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-3, c-erbB-4 and the epidermal growth factor receptor (EGFR), also known as c-erbB-1. Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-2 reactivity has been detected in proximal kidney tubules, mucosal epithelium in the gastrointestinal tract, and squamous epithelium in skin. Most normal adult tissues show little or no reactivity with antibodies against c-erbB-2. However, c-erbB-2 is overexpressed in many human breast, stomach, ovary and bladder carcinomas. EGFR, c-erbB-3 and c-erbB-4 are also overexpressed in various human tumor cells, and it is thought that aberrant activation of type 1 growth factor kinase activities may contribute to tumor progression. The antibody 3B5 recognizes human c-erbB-2. A synthetic peptide corresponding to amino acids 1242-1255 (TAENPEYLGLDVPV) in the C-terminal domain of human c-erbB-2 was used as immunogen.

Pathways: Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development